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Abstract Visceral obesity and metabolic abnormalities typ-
ical for metabolic syndrome (MS) are the new epidemic in
adolescence. MS is not only the risk factor for cardiovascu-
lar disease but also for chronic kidney disease (CKD). Thus,
there are some reasons to recognize MS as a new challenge
for pediatric nephrologists. First, hypertensive and diabetic
nephropathy, the main causes of CKD in adults, both share
the same pathophysiological abnormalities associated with
visceral obesity and insulin resistance and have their origins
in childhood. Secondly, as the obesity epidemic also affects
children with CKD, MS emerges as the risk factor for
progression of CKD. Thirdly, metabolic abnormalities typ-
ical for MS may pose additional risk for cardiovascular
morbidity and mortality in children with CKD. Finally,
although the renal transplantation reverses uremic abnor-
malities it is associated with an exposure to new metabolic
risk factors typical for MS and MS has been found to be the
risk factor for graft loss and cardiovascular morbidity after
renal transplantation. MS is the result of imbalance between
dietary energy intake and expenditure inducing dispropor-
tionate fat accumulation. Thus, the best prevention and
treatment of MS is physical activity and maintenance of
proper relationship between lean and fat mass.
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Introduction
The association between obesity, metabolic abnormalities
such as hyperglycemia, dyslipidemia, and cardiovascular
disease (CVD) has been described almost 100 years ago
and later on confirmed in the first reports from the
Framingham study [1]. In the late eighties of XX century
Reaven described pathological link explaining the patho-
genesis of CVD associated with obesity, metabolic abnor-
malities and elevated blood pressure, and indicated the
central role of hyperinsulinemia and insulin resistance (IR)
[2]. The first name of this abnormality was syndrome X,
other names used were: cardiometabolic syndrome,
Reaven’s syndrome, beer belly syndrome, cardiovascular
dysmetabolic syndrome, IR syndrome, and most commonly
used nowadays, metabolic syndrome (MS). The definition
of MS is based on the finding of at least three abnormalities
such as obesity, elevated blood pressure, low-HDL choles-
terol, hypertriglyceridemia, and hyperglycemia. However, it
has been shown that MS is associated not only with the
amount of fat tissue but rather with its distribution and
relationship between fat and lean body mass (LBM) [3–6].
Moreover, MS may concern lean subjects with a relatively
increased amount of visceral fat and decreased amount of
subcutaneous fat. Thus, the main contributor of the MS and
cardiovascular (CV) risk is disturbed body composition and
visceral adiposity [4]. Currently, there are two most widely
used definitions of MS set out by the National Cholesterol
Education Program Adult Treatment Panel III (ATP III) and
the International Diabetes Federation (IDF) (Table 1). The
main difference between them is the lack of visceral obesity
as an obligatory criterion in the ATP III definition, and the
crucial role of visceral obesity as an obligatory criterion in
the IDF definition. It causes discrepancies in results of
studies using different definitions [7]. Because of the insta-
bility of metabolic abnormalities accompanying obesity in
children, an improvement with weight loss or increase of
LBM at puberty and very low prevalence of CVD in child-
hood, the diagnosis of MS in children and adolescents was
questioned. However, pediatric obesity epidemic, increase
of blood pressure in childhood population and finding that
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metabolic abnormalities and MS are the dominant main
intermediate phenotype of primary hypertension (PH) in
children caused the greater awareness of MS in childhood
[8, 9]. Unfortunately, the uniform definition of MS was still
lacking and even more than 40 different definitions of MS
were used in pediatric studies [7]. In 2007, the IDF pub-
lished pediatric definition based on age-related cut-offs for
diagnosis of MS (Table 2) [10]. According to the IDF, MS
can be diagnosed in children older than 10 years when at
least three criteria are present with an enlarged waist cir-
cumference (WC) as the obligatory criterion.
MS is a challenge for pediatric nephrologists because of
several reasons. Firstly, the main causes of chronic kidney
disease (CKD) in adults, i.e., hypertensive and diabetic
nephropathy, share the same pathophysiological abnormali-
ties associated with visceral obesity and IR, both have
origins in childhood and obesity-related nephropathy is
now more often diagnosed in children [11–15]. Secondly,
Table 1 Definitions of metabolic syndrome issued by Adult Treatment Panel (ATP) and International Diabetes Federation (IDF)
International Diabetes Federation The US National Cholesterol Education Program
Adult Treatment Panel III
Central obesity (defined as waist circumference with ethnicity-specific values) At least three of the following:
AND any two of the following:
•Triglycerides: > 150 mg/dl (1.7 mmol/l), or specific treatment
for this lipid abnormality
•Central obesity: waist circumference ≥ 102 cm or
40 inches (male), ≥ 88 cm or 36 inches (female)
•HDL cholesterol: < 40 mg/dl (1.03 mmol/l) in males, < 50 mg/dl (1.29 mmol/l)
in females, or specific treatment for this lipid abnormality
•Dyslipidemia: TG ≥ 1.7 mmol/l (150 mg/dl)
•Systolic BP > 130 or diastolic BP >85 mmHg, or treatment
of previously diagnosed hypertension
•Dyslipidemia: HDL-C < 40 mg/dl (male),
< 50 mg/dl (female)
•Fasting plasma glucose (FPG): >100 mg/dl (5.6 mmol/l),
or previously diagnosed type 2 diabetes
•Blood pressure ≥ 130/85 mmHg
•Fasting plasma glucose ≥ 6.1 mmol/l (110 mg/dl)
If FPG is >5.6 mmol/l or 100 mg/dl, an oral glucose tolerance test is
strongly recommended, but is not necessary to define presence of the syndrome
If BMI is >30 kg/m2, central obesity can be assumed and waist
circumference does not need to be measure
HDL high-density lipoprotein; BP blood pressure; BMI body mass index
Table 2 Definition of metabolic syndrome in children – IDF criteria
Age group
(years)
Obesity (WC) Triglycerides HDL-C Blood pressure Glucose (mmol/l)
or T2DM
6 to <10 ≥90th percentile Metabolic syndrome cannot be diagnosed, but further measurements should
be made if there is a family history of metabolic syndrome, T2DM,
dyslipidemia, cardiovascular disease, hypertension, and/or obesity
10 to <16 ≥90th percentile or
adult cut-off if lower
≥1.7 mmol/l <1.03 mmol/l Systolic
(≥150 mg/dl) (<40 mg/dl) ≥130 and/or
diastolic ≥85 mmHg
≥5.6 mmol/l
(100 mg/dl) (If ≥5.6 mmol/l
or known T2DM recommend
an OGTT)
>16 Use existing IDF criteria for adults:
Central obesity (defined as waist circumference ≥ 94 cm for Europid men and ≥ 80 cm
for Europid women, with ethnicity specific values for other groups)
plus any two of the following four factors:
• raised triglycerides: ≥ 1.7 mmol/l
reduced HDL-cholesterol: <1.03 mmol/l (<40 mg/dl) in males and <1.29 mmol/l
(<50 mg/dl) in females, or specific treatment for these lipid abnormalities
• raised blood pressure: systolic BP ≥130 or diastolic BP ≥85 mmHg, or treatment
of previously diagnosed hypertension
• impaired fasting glycemia (IFG): fasting plasma glucose (FPG) ≥5.6 mmol/l
(≥100 mg/dl), or previously diagnosed type 2 diabetes
IDF International Diabetes Federation; WC waist circumference; HDL high-density lipoprotein
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as the obesity epidemic has also reached children with CKD,
MS may accelerate the progression of CKD. Thirdly, CV
complications are the main cause of morbidity and mortality
in children with CKD and MS may pose additional risk.
Finally, although the renal transplantation (Rtx) reverses ure-
mic abnormalities, it is associated with immunosuppres-
sive drug-induced metabolic risk factors.
Pathogenesis of metabolic syndrome
The main abnormalities in MS include: IR, inflammation,
endothelial dysfunction, oxidative stress, activation of the re-
nin–angiotensin–aldosterone system (RAAS) and sympathetic
nervous system. Caloric excess with dietary factors such as
fructose, trans-unsaturated fatty acids, branched-chain amino
acids, and reduced mitochondrial potential are implicated in
the pathophysiology of MS. The dominant pathophysiological
feature of MS is IR in the liver, adipose tissue, and skeletal
muscles [16]. Normally, insulin promotes glucose uptake into
muscles, adipocytes, and hepatocytes and inhibits lipolysis in
the adipose tissue. It also inhibits gluconeogenesis in the liver,
where insulin-induced phosphorylation of a forkhead box pro-
tein O1 (FoxO1) prevents the expression of genes required for
gluconeogenesis. Insulin also stimulates the activation of the
transcription factor SREBP-1c, leading to transcription of
genes required for triglycerides (TTG) and fatty acids (FA)
production. Hepatic IR selectively removes the blockade of
FoxO1 by insulin what increases gluconeogenesis and in-
creases activation of SREBP-1c. The end result is increased
synthesis of FA and TTG. Because of IR, insulin is unable to
suppress lipolysis in the adipose tissue. It results in the release
of more free FA into the plasma. The “portal theory” of MS is
based on the phenomenon of venous drainage of the visceral
adipose tissue directly into the portal system. The excess
visceral fat causes the liver to be flushed with FA, which
further enhances IR. The increased amount of free FA must
be oxidized or stored and the excess TTG is secreted as very
low density lipoprotein (VLDL). In muscles, IR reduces glu-
cose uptake. IR is also modulated by hyperleptinemia or leptin
resistance, adiposity-induced inflammation, and endothelial
dysfunction [16].
Oxidative stress, probably as a secondary phenomenon,
plays a significant role in the pathogenesis of childhood MS
[17, 18]. High glucose and FA levels increase mitochondrial
reactive oxygen species in endothelial cells, which may
contribute to tissue dysfunction by dysregulation of signal-
ing pathways or by oxidative damage to biological struc-
tures. Hyperleptinemia and angiotensin II activate the
sympathetic nervous system. It decreases muscle blood
flow, increases oxidative stress and insulin resistance.
Specifically, angiotensin II inhibits insulin-mediated
phosphatidylinositol-3-kinase. It leads to IR and lower
glucose uptake, and to decreased endothelial nitric oxide
production [19]. Moreover, RAAS is involved in activation
of both inflammation, IR, and oxidative stress. This phenom-
enon has been shown in spontaneously hypertensive rat
(SHR), which is a model of genetic hypertension that allows
a study of primary hypertension. It was shown that SHR fed a
high-fructose diet developed MS, subclinical inflammation,
and oxidative stress greater than in SHR fed a normal diet
[20]. Studies in children with PH have shown that subclinical
inflammatory activity is associated with MS [21]. Moreover,
after 1 year of non-pharmacological and pharmacological
treatment with the use of angiotensin convertase inhibitors
(ACEi) or angiotensin receptor blockers (ARB), the preva-
lence of MS decreased by 50 %, immune activity normalized,
and regression of target organ damage correlated with the
decrease of WC [6]. These findings indicate strong synergy
between visceral obesity/altered body composition, IR, oxi-
dative stress, and inflammatory activation [22].
CKD and uremia modulate the above-mentioned metabolic
and immune mechanisms by influencing the secretion of
appetite-regulating hormones such as leptin, ghrelin, obestatin,
and adiponectin [23]. CKD leads to changes in plasma levels
of these hormones due to retention and altered metabolism.
There are only a few pediatric studies analyzing relationships
among appetite regulating hormones in children with CKD. In
addition, they are biased by significant differences in body
mass index (BMI) between healthy control children and
CKD children. Nevertheless, serum levels of total ghrelin, an
orexigenic and anti-inflammatory hormone, were significantly
increased in children with CKD and on dialysis in comparison
with healthy control children and children after Rtx [24].
However, plasma levels of acylated ghrelin (the active form
of the hormone) were the same as in the control group, whereas
the deacylated form of ghrelin was increased [25]. In contrast
to acylated ghrelin, desacylated ghrelin is associated with
malnutrition. Similarly, obestatin (an antiorexigenic hormone)
levels were increased and leptin levels were the same as in the
control group despite significantly lower BMI of children with
CKD. It was shown that increased leptin levels were
associated with fat mass, local and systemic inflammation,
and MS in dialyzed patients [26–28]. Because obestatin is an
antiorexigenic hormone and leptin is both an antiorexigenic
and pro-inflammatory hormone, such alterations indicate that
in CKD, metabolic equilibrium is moved towards anorexigen-
ic, pro-inflammatory, and IR effects.
Recently, new hypotheses linking alterations in central
nervous system regulation of cardiovascular system and
immuno-metabolic abnormalities in the form of MS have
been proposed [29, 30]. In short, there is evidence that
increased sympathetic activity from cardiovascular net-
works in the brain, as is present during chronic stress or in
depression, is associated with the development of obesity,
and visceral obesity in particular, and immune activation
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and cytokines secretion may have direct effect on central
sympathetic activation.
The pathological basis of cardiovascular complications
in chronic kidney disease
CVD is the main cause of death in CKD in both adults and
children [19]. Because CKD in adults is caused by hyperten-
sive and diabetic nephropathy, CVD is the main clinical prob-
lem already before late stages of CKD [31]. On the contrary, in
children with CKD, the clinically evident CVD develops at the
late stages of disease, usually in dialyzed patients [32]. The
pathogenesis of CVD differs in relation to the stage of CKD. In
advanced CKD, CVD is caused by three overlapping process-
es: atherosclerosis, uremic arteriosclerosis, and uremic cardio-
myopathy. In 1974, Lindner et al. reported that hemodialyzed
adults suffered from accelerated atherosclerosis [33]. However,
although both atherosclerosis and uremic arteriosclerosis share
the same risk factors as hypertension, dyslipidemia,
hyperhomocysteinemia, and low-level inflammation, etc., the
basic mechanisms are different. Atherosclerotic arterial injury
starts in the endothelium and the main risk factor is
dyslipidemia, which leads to infiltration of arterial wall by
lipids, inflammatory reaction, and development of atheroscle-
rotic plaque. Hypercholesterolemia, and especially atherogenic
dyslipidemia with elevated low density lipoprotein (LDL) cho-
lesterol, hypertriglyceridemia, and low-high density lipoprotein
(HDL) cholesterol, is the most important factor and even in the
absence of other factors leads to atherosclerosis. The other risk
factors such as hypertension, IR, smoking, etc., which cause
mechanical damage to the endothelial layer, facilitate lipids
infiltration and accelerate the process [34]. Atherosclerosis is
focal and refers to large- and medium-sized arteries. The heart
is damaged by repeated episodes of ischemia.
In contrast, uremic arteriopathy begins in the medial layer
of the arterial wall (Fig. 1). The process is diffuse and affects
the entire arterial tree. The main risk factor of uremic
arteriopathy is a low glomerular filtration rate (GFR) with
its consequences such as secondary hyperparathyroidism
leading to calcium and phosphate homeostasis disturbances.
The crucial step in pathogenesis of uremic arteriopathy is
the process of differentiation of vascular smooth muscle
cells in the medial layer of arterial wall into osteoblast-like
cells [35–38]. Arteriopathy accelerates with the start of
dialysis and increases with age [38, 39]. Experimental stud-
ies showed that an atherogenic diet caused hyperlipidemia
both in subtotally nephrectomized and sham-operated rats
but it was more pronounced in uremic rats. However, de-
spite hyperlipidemia with the increase of VLDL and LDL
cholesterol concentrations, lipids concentrations were not
increased in arterial walls of uremic rats [40]. A comparison
of coronary arteries of patients who died with normal renal
function and arteries of dialyzed patients showed that ure-
mic patients had greater thickness of the medial layer of
coronary arteries. Moreover, lesions in uremic patients were
characterized by the presence of calcified plaques and a
smaller number of plaques with extracellular lipid deposits
[41]. The aortas of uremic patients also had greater calcium
and phosphorus content and greater expression of markers
of osteoblast phenotype transformation even in non-
calcified areas than the aortas of non-uremic patients. It
was accompanied by lesser deposition of fetuin A in uremic
aortas which indicates that system of natural inhibitors of
calciphylaxis is involved in pathogenesis of uremic
arteriopathy [42]. In children with uremic arteriopathy,
increased carotid intima media thickness (cIMT) and stiff-
ness of common carotid artery correlated with decreasing
GFR [35]. Although low HDL-cholesterol, apoproteins A
and B correlated with cIMT, none of these factors was found
as an independent predictor of IMT.
The basis for development of uremic cardiomyopathy is
diffuse intermyocardiocyte fibrosis (Fig. 2). The main risk
factors for uremic cardiomyopathy are the same as for
uremic arteriopathy, and both uremic arteriopathy and car-
diomyopathy are exaggerated by traditional CV risk factors
and accelerate in CKD stage 5 [43].
The different pathological basis of CV complications
caused by uremia and of those caused by metabolic abnor-
malities typical of MS leading to atherosclerosis explain the
discrepant results of treatment with anti-atherosclerotic
drugs in relation to stage of CKD.
The prevalence of metabolic syndrome among children
and adolescents.
Using the IDF definition, US National Health and Nutrition
Survey data from 1999–2004 showed that among adolescents
aged 12–17 years, the prevalence of MS was 4.5 %. It
increased from 1.2 % in 12 years old to 7.1 % in 16–17 years
old [44]. In the EuropeanYouth Heart Study, the prevalence of
MS defined according to the IDF was 0.2 % in 10-year-old
and 1.4 % in 14-year-old children [45]. Similar data on the
prevalence of MS among 10-year-old children were reported
in Greece [46]. In Poland, the prevalence of MS among
adolescents from urban population ranged from 1.4 to
2.2 %, but among children with PH was ten times higher than
in the general population and ranged from 15 to 20 % [6, 8].
The prevalence of metabolic abnormalities
and metabolic syndrome in CKD
Metabolic abnormalities, changes in body composition with
growth failure, the decrease of LBM, and the increase of
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visceral fat correlate with decreasing GFR. However, there
are relatively scanty data on the prevalence of MS in chil-
dren with CKD. Children with CKD are shorter and weigh
relatively more than healthy children, which is evident from
stage 3 CKD [47–49]. This effect is now modulated by
environmental and lifestyle changes and it was reported that
children with CKD are more overweight nowadays than two
decades ago [50, 51]. Dyslipidemia and glucose intolerance
are typical metabolic abnormalities of CKD. Reports from
the CKID Study indicate that the most typical abnormality
in children with CKD stage 2–4 is hypertriglyceridemia
[52]. It was estimated that every 10 ml/min/1.73 m2 de-
crease of GFR was associated with an increase of serum
concentration of TTG by 8 %, an increase of LDL choles-
terol concentration by 2 %, and a decrease of HDL choles-
terol concentration by 3 %. Proteinuria was associated with
these abnormalities and they occurred in children with ne-
phrotic proteinuria twice more often compared to non-
proteinuric children.
Another analysis from the CKID Study revealed that 46 %
of children with CKD stage 2–4 had hypertension, 44 % had
dyslipidemia, 15 % were obese, and 21 % presented with
disturbed glucose metabolism. At least three aforementioned
cardiovascular risk factors were found in 13 % of patients [53].
Therefore, according to some definitions, the prevalence of
MS in this cohort may be estimated as about 13 % what is
greater than in general pediatric population. However, this is
still much lower than in adults with CKD. Kwan et al. found
that in adults with mean GFR 46 ml/min/1.73 m2 the preva-
lence of MS ranged from 9 to 58 % across BMI values from
below 20 to above 35. In contrast, in adults with mean GFR
87 ml/min/1.73 m2 the prevalence of MSwas 1 to 35% across
the same ranges of BMI [54]. Wu et al. foundMS in 50.5 % of
dialyzed adults when the ATP III definition was used, and in
30.8 % when the IDF definition was used [55]. As in the
general population, MS significantly increases CV risk in
adults with CKD and even in dialyzed patients. Recent study
indicates that abdominal obesity as measured using WC was
Fig. 1 Left uremic arteriopathy.
Aortic wall of 20-year-old boy
dialyzed for 8 years.
Thickening of media of aortic
wall. Normal endothelium.
Right Atherosclerosis of renal
artery in 60-year-old man
(courtesy of Dr. W.
Grajkowska)
Fig. 2 Left normal
myocardium. Right Myocardial
biopsy of 13-year-old girl




(double arrows) and steatosis.
Amount of connective tissue –
3 % (normal 1 %) (courtesy of
Dr. W. Grajkowska)
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the most significant predictor of CV events in hemodialyzed
adults [55]. It must be pointed out that the relationship between
obesity, BMI, and CV risk in dialyzed patients is curvilinear.
The CV morbidity and mortality is increased among dialyzed
patients with low and even normal BMI in comparison with
patients who had elevated BMI. However, detailed analysis
revealed that the protective effect of high BMI was limited to
patients with normal or high muscle mass [56].
Metabolic syndrome in children after renal
transplantation
Normalization of metabolic abnormalities caused by uremia
and even some reversal of uremic arterial and cardiac damage
after Rtx depends on GFR of transplanted kidney [57, 58].
However, the immunosuppressive therapy to prevent organ
rejection also causes significant metabolic abnormalities such
as atherosclerotic dyslipidemia, IR, and the risk of new-onset
diabetes after transplantation (NODAT). These abnormalities,
typical for MS, are accompanied by visceral obesity and the
decrease of LBM. Therefore, the resultant depends on GFR
and the side effects of immunosuppressive drugs.
The average prevalence of MS in adults after Rtx is ap-
proximately 60–70 %. Obesity is the main risk factor for the
development of MS after Rtx and MS increases CV risk [59,
60]. The averaged results from pediatric studies indicate that
the prevalence of MS significantly increases after Rtx and is
higher compared to the general population and in dialyzed
children. Wilson et al. reported that the prevalence of MS in
children 1 year after Rtx was 37.6 % and two-thirds of them
developed MS de novo [61]. Höcker et al. found that the
prevalence of MS after Rtx depended on a time from Rtx
and the use of corticosteroids (CS) and ranged from 40 % in
the first months after Rtx to 20 % after 2 years [62].
Children after Rtx who had MS also had greater left
ventricular mass and left ventricular hypertrophy developed
in 55 % of them compared with 32 % without MS [61]. The
eccentric left ventricular hypertrophy, typical for obesity and
MS, was found in 34 % of children with MS, compared with
15 % in children without MS.
MS after Rtx is associated with lower graft survival rates
[63, 64]. Maduran et al. reported that irrespective of CS
usage, children who had MS also had significantly lower
GFR [65].
CS play a crucial role in the pathogenesis of MS after
Rtx. Höcker et al. showed that in patients in whom cortico-
steroids were withdrawn, the prevalence of MS fell to 5 %
after 1 year [62]. Similarly, an exposure to MS factors
significantly decreased in this group in comparison to chil-
dren in whom treatment with CS was continued. The use of
greater doses of CS is a derivative of HLA matching and
rejection episodes. It was found that MS prevalence was
three times lower among recipients of living donor grafts
than among recipients of cadaver donor grafts [66].
The most severe metabolic complication of CS after Rtx is
NODAT. It seems that the first description of NODAT after
Rtx was given by Starzl in 1964 [67]. Although azathioprine
usage is also associated with a pancreatic injury, it seems that
the prevalence of NODAT increased significantly with the
introduction of calcineurin inhibitors (CNI) in mid-eighties
of XX century [68]. Cyclosporin (CSA) and especially
tacrolimus (TAC) have the potential to directly damage pan-
creaticβ cells [69]. A comparison of registry data from the last
three decades suggests that the prevalence of NODAT in-
creased from below 10 % in the 1980s to 20-30 % in the last
decade [70]. The US Renal Data System analysis showed
that the prevalence of NODAT in transplanted children
increased from 2-3 % in the late-1980s to 7.5 % recent-
ly [71]. The NAPRTSC report showed an increased
prevalence of NODAT in children after Rtx, however
the change presented only statistical tendency [72].
Nevertheless, both reports indicate the trend for an
increased prevalence of NODAT in transplanted children
in the last decades.
The pathogenesis of NODAT is multifactorial and all
risk factors for diabetes including CS and CNI play a
role. TAC is a stronger risk factor for NODAT than
CSA [72]. However, the risk factors for NODAT operate
already during dialysis period, and include peritoneal
dialysis and obesity [73]. The other risk factor is hy-
perglycemia during the postoperative period [74].
Peritoneal dialysis, overweight, the usage of CNI and
posttransplant hyperglycemia seem all to be risk factors
of NODAT.
Metabolic syndrome as a risk factor of CKD in children
Because the number of nephrons does not increase with
increasing body fat, obesity must cause the increase of
single-nephron GFR, and the absolute values of GFR should
increase as a consequence of increased GFR and filtration
fraction. Chagnac et al. reported that GFR was 51 % greater
in obese non-diabetic adults than in non-obese, healthy con-
trols. It was associated by proportionally lower (on average
31 %) increase in renal plasma flow and was accompanied by
slightly increased but still in normal range mean arterial pres-
sure. This resulted in a filtration fraction of 17 % in obese in
comparison with 15 % in non-obese subjects [75]. Chagnac et
al. [75] found that ultrafiltration coefficient did not change.
The other finding was that the obese subjects were exposed to
the greater glucose and insulin concentrations expressed as the
areas under the curves after oral glucose load. The changes in
glomerular hemodynamics have been confirmed by clinical
observations. MS and its main criteria associate with CKD
208 Pediatr Nephrol (2014) 29:203–216
and are predictors for incident of CKD in adults. The best
confirmation of this pathogenical link is hypertensive and
diabetic nephropathy as the main causes of CKD [76, 77].
Each criterion of MS is associated with the risk of CKD,
however, hypertension has the greatest impact [77]. Most of
the studies evaluat ing the relat ionship between
anthropometrical parameters and the risk of CKD analyzed
only BMI. It was found that BMI together with other factors
such as diabetes, smoking, and low GFR was associated with
the risk of CKD [78, 79]. However, when other parameters of
adiposity such as WC were analyzed, it was shown that the
renal risk associated with MS was not associated with in-
creased BMI but with visceral obesity and the probability of
incident CKD increased from the lowest to highest WC quar-
tile [80]. Similarly, in the Diabetes Control and Complications
Trial, it was found that every 10-cm increase in WC was
associated with a 35 % increased risk of incident albuminuria
in adults with type 1 diabetes [81].
The time delay between exposure to metabolic abnormal-
ities and kidney injury explains that the first abnormalities are
only surrogate markers of progressive CKD. It was found that
in obese children and children with non-alcoholic fatty liver
disease, exposure to MS criteria impaired glucose tolerance
and IR correlated with microalbuminuria and hyperfiltration
[82–84]. Kolouridis et al. found that the exposure to the MS
criteria correlated positively with GFR. However, GFR de-
creased when children were exposed to more than four MS
criteria [85]. Prospective study of adolescents and young
adults (mean age 18 years) found that being overweight,
hypertension, and low-HDL cholesterol concentration in-
creased the probability of hyperfiltration 6.6-fold. Moreover,
high metabolic risk correlated with hyperfiltration and preced-
ed development of overt nephropathy [86]. The general con-
clusion is that the first abnormality observed in children with
MS is hyperfiltration, and albuminuria develops at later stages
followed by the decrease of GFR.
Although the pathogenesis of progressive renal injury
related to MS is multifactorial it is at least partly explained
by phenomena observed in obesity-related glomerulopathy
(ORG). The first report on the relationship between obesity
and kidney injury came from Preble who reported in 1923
that obesity was associated with proteinuria [87]. However,
Weisinger et al. first described both clinical course and biopsy
findings in kidneys of four obese adults who presented with
MS and nephrotic proteinuria [88]. Proteinuria decreased with
weight loss but in patients who re-gained weight proteinuria
reappeared. Cardiac catheterization found an increased
right atrial pressure. The renal biopsies revealed segmental
sclerosis.
The dominant microscopical finding and probably the
first stage of ORG is glomerulomegaly (Fig. 3). The seg-
mental sclerosis beginning in the hilar region is probably the
next stage of the disease. In contrast to idiopathic focal
segmental glomerular sclerosis (FSGS), ORG-FSGS is as-
sociated with much more advanced arteriolosclerosis [14].
The immunofluorescence is usually negative or showed
modest IgM and C3 deposits. In some cases of ORG-
FSGS, electron microscopy showed intramembrane fibrin
deposition. The podocytes can be hypertrophied, their pro-
cesses can be modestly fused, some podocytes can be de-
tached, and neo-membrane is formed. In some reports,
reduced podocyte density and number correlated with the
severity of proteinuria [89]. Glomeruli cells obtained from
biopsy specimens of patients with ORG presented with
greater expression of genes related to lipid metabolism,
pro-inflammatory cytokines, vascular endothelial growth
factor gene, and its receptor 2 [90]. With the rise of the
obesity epidemic, ORG is now more often recognized and
the incidence of biopsy-proven ORG in adults increased
tenfold between 1986 and 2000 [14]. The progressive
course of ORG with a decrease of GFR was also observed
in obese children [15]. In both adults and children with
ORG, proteinuria decreased or even normalized after weight
loss and/or RAAS blockade. A normalization of proteinuria
has also been reported after bariatric surgery in a morbidly
obese girl with biopsy-proven ORG-FSGS [91]. However,
histological deterioration was observed despite weight loss
and normalization of proteinuria in two biopsy samples
taken from a 13-year-old girl at the time of diagnosis of
ORG and after 2 years [92].
Historically, the pathogenesis of renal injury in ORG and
ORG-FSGS was explained as a consequence of increased
venous pressure documented by increased right atrial pres-
sure and modest hypoxemia caused by accompanying sleep
apnea [88]. However, the functional studies that document-
ed hyperfiltration with increased intraglomerular pressure
and albuminuria preceding overt proteinuria fits well with
the hyperfiltration theory. Moreover, an elevated blood pres-
sure, arteriolopathy, and exposure to MS are similar to the
pathogenesis of hypertensive nephropathy and nephropathy
in type 2 diabetes. Thus, MS will cause an additional burden
especially in patients with CKD suffering already from low
nephron number due to disease or prematurity.
Treatment of metabolic syndrome and metabolic
abnormalities in children with CKD
Treatment of MS, both in the general population and in
children with CKD, is aimed at reversal of IR and normal-
ization of metabolic and hemodynamic abnormalities. It
may be achieved by reduction of mitochondrial load by a
decrease of substrate availability, a decrease of FA flux to
the liver, and an increase in the number of mitochondria
[16]. The first aim may be achieved by caloric restriction
with dietary modification leading to the decrease of the
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glycemic index. An increased amount of fiber in the food
may decrease FA flux. Physical exercise and an increase in
LBM lead to the formation of new mitochondria in the liver
and in skeletal muscles. Dietary modifications with signifi-
cant limitations of sugar, and especially of fructose, in the
diet, has been found effective in terms of both the normal-
ization of metabolic abnormalities, decrease or stabilization
of cIMT, and improvement of endothelial function assessed
by flow-mediated dilation (FMD) in children with MS [93,
94]. However, when dietary modifications and physical
exercise were combined, FMD of the brachial artery was
much more improved. The important observation is that
after stopping of an exercise program, FMD decreased to
basal values [94]. In adolescents with PH and MS, 1 year of
non-pharmacological treatment based on physical activity
alone or combined with blockade of RAAS resulted in a
decrease of the prevalence of MS by 50 % and the main
predictor of improvement was the decrease of WC [6].
Non-pharmacological treatment strategies
There are only a few reports on the effectiveness of the non-
pharmacological treatment of MS in children with CKD or
after Rtx. As in other chronic diseases, children with CKD
are less physically active and have lower cardiorespiratory
fitness assessed as maximal oxygen uptake in comparison
with healthy children [95]. The analysis of children and
adolescents with CKD, on dialysis and after Rtx, has shown
that physical activity was uniformly low in all three groups.
In addition, females were less active than males and older
patients, aged 18–20 years, had significantly lower physical
activity in comparison with younger patients. Moreover, the
results of a standardized 6-min walk distance test were
below 2 and 4 standard deviations from the mean of normal
values in boys and girls, respectively. The level of physical
activity was associated negatively not only with BMI but
also positively with maternal education level [96]. In adults
with pre-dialysis CKD and on dialysis, effective physical
activity treatment caused an increase in cardiorespiratory
fitness, a decrease of WC, and an increase in LBM [97].
Such changes associate with an improved biochemical pro-
file [98]. Similarly, in children with CKD, on dialysis and
after Rtx, implementation of programs of physical activity
resulted in cardiorespiratory fitness improvement, a de-
crease of blood pressure, and left ventricular mass [99].
However, children after Rtx had to be physically active for
at least 3–5 h/week to attain cardiorespiratory fitness of
healthy children who led a sedentary life-style (physical
activity below 3 h/week). Although there are no recommen-
dations prepared especially for children with CKD, general
pediatric recommendations advise that daily physical activ-
ity should be at least 60–90 min of accepted anaerobic
exercise [100]. One of the limiting factors of the anabolic
effect of exercise and increase of lean body mass in CKD
patients is acidosis [101]. The other limiting factor of life-
style interventions in children with CKD and after Rtx is
non-compliance. It was reported that half of all children
after Rtx declined to participate in physical activity program
and none of the patients complied with dietary limitations
Fig. 3 Renal biopsy from a
14-year-old severely obese girl
with proteinuria, hyperuricemia,
and metabolic syndrome. She
was dialyzed at 20 years old
and transplanted at 21. 200×
(courtesy of Dr. P. Kluge)
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[102]. Nevertheless, it must be stressed that the lifestyle
interventions in the treatment of MS, although difficult to
implement, have been shown to be more efficient than
pharmacological treatment [103].
Pharmacological treatment strategies
Potentially available pharmacological interventions in MS
rely on the treatment of dyslipidemia, IR, and arterial hy-
pertension. Although elevated LDL cholesterol is not a
criterion of MS, it is commonly observed in children with
MS and CKD or after Rtx.
Treatment of dyslipidemia
Statins lower both total cholesterol, LDL cholesterol, and, to a
lesser extent, TTG concentrations. In adults with CKD, statins
are effective both in lowering LDL cholesterol and decreasing
the incidence of CV events. However, this beneficial effect
was observed only in patients with CKD stage 2–4. In dia-
lyzed patients, statins led to a decrease of LDL cholesterol
concentrations but it did not affect CV morbidity and mortal-
ity except of patients with diabetes [104, 105]. In the SHARP
study, simvastatin with ezetimibe reduced CVevents and CV
mortality but only those caused by atherosclerosis and not by
uremic arteriopathy [106]. Similarly, statins used after Rtx
decrease the risk associated with atherosclerosis but the main
risk is still related to the low GFR and uremic arteriopathy
[107]. It is not unexpected in light of different pathological
basis of CVD in CKD and on dialysis, as discussed above.
Statins used in children with familial hypercholesterolemia
reduced both total and LDL cholesterol and cIMT [108].
Simvastatin used in a non-homogenous group of children with
CKD and with modestly reduced GFR led to a reduction of
total (by 23 %), LDL cholesterol (by 34 %), and TTG (by
21 %) concentrations [109]. However, in a small cross-over
trial of atorvastatin in eight children with CKD and GFR
below 60 ml/min/1.73 m2, despite a significant lowering of
LDL cholesterol, there was no change in flow-mediated dila-
tion of brachial artery [110].
The drugs of choice in the treatment of hypertriglyc-
eridemia are fibrates or niacin. As in the case of statins,
fibrates used in adults with mild to moderate CKD reduced
CV events and, similarly to statins, were renoprotective.
However, fibrates also did not reduce CV events in patients
on dialysis [111]. There are only a few reports on use of
fibrates in children. Nevertheless, a treatment algorithm for
the use of fibrates in children was proposed [112].
According to it, in any case, except of TTG levels above
900 mg/dl, the first step should be life-style and dietary
modifications with a significant decrease of sugar
consumption.
Recommendations on treatment of dyslipidemia in children
from high-risk groups
The American Heart Association (AHA) issued recommen-
dations on the treatment of children from high-risk groups
including CKD, children with dyslipidemia, and children
with MS [17, 102, 113]. The AHA Expert Panel
recommended to stratify cardiovascular risk in relation to
the family history of CVD and presence of comorbidities
such as obesity, hyperglycemia, hypertension, dyslipidemia,
and low physical activity. In the case of presence of the
above-mentioned comorbidities/risk factors, the AHA rec-
ommends treatment (both non-pharmacological and phar-
macological) to achieve LDL cholesterol below 100 mg/dl,
normoglycemia, normal weight, and normal blood pressure.
In patients without additional risk factors, LDL cholesterol
should be lowered below 130 mg/dl. The AHA recommends
using statins if LDL cholesterol is above 130 mg/dl, despite
dietary intervention. Simvastatin and atorvastatin are metab-
olized by cytochrome P450 3A4 and pravastatin and
fluvastatin can be metabolized also by alternative metabolic
routes. Involvement of cytochrome P450 in statin metabo-
lism interacts with CNI metabolism, especially with CSA. It
was found that in adults after Rtx who were treated with
atorvastatin, plasma concentrations of atorvastatin increased
sixfold and the CSA area under curve decreased by 9.5 %
[114]. According to the 2009 AHA statement on MS in
children, fibrates or niacin should be used if triglyceride
levels are above 1,000 mg/dl despite dietary and life-style
modifications [18]. Because of the possibility of adverse
reactions of both statins and fibrates, especially of rhabdo-
myolysis, their use should be carefully considered.
Despite the existing recommendations, the use of phar-
maceutical products to treat dyslipidemia in children with
CKD and MS is controversial. Due to the different etiology
of CKD and pathogenesis of CVD in children with CKD,
expert statements do not recommend wide use of statins in
children with CKD [115]. Moreover, the recent meta-
analyses showed that statins used longer than 1 year in-
crease by 9 % the risk of incident diabetes and intensive
treatment increases this risk by additional 12 % [116, 117].
In children after Rtx and with MS, typical atherogenic
dyslipidemia may coexist with MS. Thus, life-style interven-
tions may be successfully combined with statins and/or
fibrates. The best option is use of the lowest possible dose
of CS or CS-free immunosuppressive protocol, if possible.
Anti-obesity drugs
Anti-obesity drugs may be the option in children with severe
obesity. However, it must be pointed out that only orlistat is
licensed for use in the treatment of obese adolescents.
Moreover, orlistat has limited efficiency and produces
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significant side effects [118]. Sibutramine, an anti-appetite
drug, has been withdrawn because of severe cardiovascular
toxicity.
Insulin sensitizers
Theoretically, insulin sensitizers seem to be the best pharma-
cological option in MS [119]. In contrast to adult studies, there
are only a few reports on the use of metformin in children with
CKD. Metformin is used in children with MS and glucose
levels above 126 mg/dl when non-pharmacological treatment
is ineffective [18]. Because of a relatively safe profile when
GFR is above 60 ml/min/1.73 m2, it may be of help in treat-
ment of children with MS and risk of incident CKD. However,
use of metformin in CKD is limited by decreased elimination.
In patients with GFR below 40 ml/min/1.73 m2, there is more
than a 10 % risk of lactic acidosis. Thiazolidinediones, the
other insulin sensitizers, may cause hypoglycemia [120].
Nevertheless, the use of thiazolidinediones in diabetic adults
on dialysis was associated with significantly lower mortality in
patients who were insulin independent but not in those who
required insulin treatment [121].
Antihypertensive drugs
Treatment of elevated blood pressure in children with MS
and with CKD or after Rtx should take into account the
pathogenetic mechanisms of hypertension, metabolic abnor-
malities, and potential renoprotective effects. It has been
shown both in experimental studies and in clinical trials that
blockade of RAAS leads to significant improvement of
insulin sensitivity and normalization of metabolic abnormal-
ities [122]. In addition, it was shown that chronic use of
ACEi was associated with a lower rate of development of
type 2 diabetes in middle age and older adults with arterial
hypertension [123]. Thus, the drugs of choice in the treat-
ment of hypertension in children with MS are ACEi or
angiotensin 2 receptor type 1 blockers (ARB) [124]. In
children with CKD, RAAS inhibitors have also
renoprotective effect [125]. However, efficacy of
ACEi/ARBs in monotherapy decreases with decrease of
GFR and with sodium retention. If monotherapy with
ACEi/ARBs is not sufficient, the choice of second and third
drug should also take into account metabolic effects.
Dihydropyridine calcium channel blockers have lower
renoprotective potential but are devoid of adverse metabolic
effects and may be used together with ACEi or ARBs.
Similarly, alpha-adrenolytics also have beneficial metabolic
profiles. In contrast, beta-adrenolytics aggravate metabolic
abnormalities including IR [126]. However, so known
vasodilating beta-adrenolytics such as nebivolol have sig-
nificantly better metabolic profiles in comparison with older
beta blockers such as metoprolol [127]. Nevertheless, in
children who have volume-dependent hypertension, di-
uretics may be the last and best option.
Conclusions
In conclusion, from a practical point of view, the best and
safest way of prophylaxis and therapy of MS in children with
CKD, on dialysis and after Rtx, is physical activity and dietary
modifications. Life-style modifications, when successfully
implemented, have greater effects than pharmacological
therapy. ACEi or ARBs lower blood pressure, slow progres-
sion of CKD, and seem to improve metabolic abnormalities.
Pharmacological intervention for dyslipidemia and impaired
glucose tolerance/IR should be limited to cases when non-
pharmacological treatment is not effective. In children after
Rtx minimal dose of CS or CS free protocol is the best option
both in prevention and treatment of MS.
Questions (answers are provided following the reference
list)





d) increased waist circumference
e) a and d
2. The prevalence of MS in children after Rtx
a) is lower than in general population
b) is the same as in general population
c) is higher than in general population and the same as
in children on dialysis
d) is higher than in general population and higher than
in children on dialysis
e) is the same as in children on dialysis
3. The clinical presentation of obesity-related glomerulopathy
is
a) severe arterial hypertension, hematuria, proteinuria
b) hematuria with proteinuria
c) isolated proteinuria
d) severe nephrotic syndrome with rapidly declining
renal function
e) non-proteinuric, slowly progressive CKD
4. The most important risk factors of NODAT are:
a) preemptive kidney transplantation
b) use of high doses of corticosteroids and calcineurin
inhibitors
c) previous long treatment with peritoneal dialysis
212 Pediatr Nephrol (2014) 29:203–216
d) CAKUT as primary renal disease
e) b and c
5. Prevention and treatment of MS in CKD and after Rtx
should be based on:
a) metformin
b) intensive antihypertensive treatment with ACEi/ARBs
plus metformin
c) increased physical activity plus metformin
d) increased physical activity, dietary modifications and
ACEi/ARBs in the case of elevated blood pressure
e) only ACEi
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